The Anticancer Properties of Herba Epimedii and Its Main Bioactive Componentsicariin and Icariside II

被引：79

作者：

Chen, Meixia ^{[1
]}

Wu, Jinfeng ^{[2
]}

Luo, Qingli ^{[1
]}

Mo, Shuming ^{[1
]}

Lyu, Yubao ^{[1
]}

Wei, Ying ^{[1
]}

Dong, Jingcheng ^{[1
]}

机构：

[1] Fudan Univ, Huashan Hosp, Dept Integrat Med, Shanghai 200040, Peoples R China

[2] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200040, Peoples R China

来源：

NUTRIENTS | 2016年 / 8卷 / 09期

基金：

中国国家自然科学基金;

关键词：

anticancer properties; Herba Epimedii; icariin; icariside II; FACTOR-KAPPA-B; INDUCED APOPTOSIS; CELL-CYCLE; DOWN-REGULATION; CONSTITUTIVE ACTIVATION; THERAPEUTIC TARGETS; SIGNALING PATHWAYS; ARSENIC TRIOXIDE; ICARIIN EXERTS; TUMOR-GROWTH;

D O I：

10.3390/nu8090563

中图分类号：

R15 [营养卫生、食品卫生]; TS201 [基础科学];

学科分类号：

100403 [营养与食品卫生学];

摘要：

Cancer is one of the leading causes of deaths worldwide. Compounds derived from traditional Chinese medicines have been an important source of anticancer drugs and adjuvant agents to potentiate the efficacy of chemotherapeutic drugs and improve the side effects of chemotherapy. HerbaEpimedii is one of most popular herbs used in China traditionally for the treatment of multiple diseases, including osteoporosis, sexual dysfunction, hypertension and common inflammatory diseases. Studies show HerbaEpimedii also possesses anticancer activity. Flavonol glycosides icariin and icariside II are the main bioactive components of HerbaEpimedii. They have been found to possess anticancer activities against various human cancer cell lines in vitro and mouse tumor models in vivo via their effects on multiple biological pathways, including cell cycle regulation, apoptosis, angiogenesis, and metastasis, and a variety of signaling pathways including JAK2-STAT3, MAPK-ERK, and PI3k-Akt-mTOR. The review is aimed to provide an overview of the current research results supporting their therapeutic effects and to highlight the molecular targets and action mechanisms.

引用

页数：19

共 103 条

[31]

Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8

[32]

Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations [J].

Han, Woody ;

Lo, Hui-Wen .

CANCER LETTERS, 2012, 318 (02) :124-134

[33]

Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis [J].

Hsiao, JR ;

Jin, YT ;

Tsai, ST ;

Shiau, AL ;

Wu, CL ;

Su, WC .

BRITISH JOURNAL OF CANCER, 2003, 89 (02) :344-349

[34]

Icariin inhibits oxidized low-density lipoprotein-induced proliferation of vascular smooth muscle cells by suppressing activation of extracellular signal-regulated kinase 1/2 and expression of proliferating cell nuclear antigen [J].

Hu, Yanwu ;

Liu, Kai ;

Yan, Mengtong ;

Zhang, Yang ;

Wang, Yadi ;

Ren, Liqun .

MOLECULAR MEDICINE REPORTS, 2016, 13 (03) :2899-2903

[35]

Hu YW, 2015, INT J CLIN EXP MED, V8, P3585

[36]

Induction of Apoptosis by Icariside II through Extrinsic and Intrinsic Signaling Pathways in Human Breast Cancer MCF7 Cells [J].

Huang, Chaoqing ;

Chen, Xiaoguang ;

Guo, Baolin ;

Huang, Wenhua ;

Shen, Ting ;

Sun, Xinguang ;

Xiao, Peigen ;

Zhou, Qing .

BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2012, 76 (07) :1322-1328

[37]

Simultaneous determination of nine flavonoids and qualitative evaluation of Herba Epimedii by high performance liquid chromatography with ultraviolet detection [J].

Huang, Hao ;

Liang, Mingjin ;

Zhang, Xinmin ;

Zhang, Chuan ;

Shen, Ziyin ;

Zhang, Weidong .

JOURNAL OF SEPARATION SCIENCE, 2007, 30 (18) :3207-3213

[38]

A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells [J].

Huang, Xin ;

Zhu, Danyan ;

Lou, Yijia .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 564 (1-3) :26-36

[39]

Death and anti-death: Tumour resistance to apoptosis [J].

Igney, FH ;

Krammer, PH .

NATURE REVIEWS CANCER, 2002, 2 (04) :277-288

[40]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]

← 1 2 3 4 5 6 7 8 9 10 →